-
Company Insights
NewStripe – Competitor Profile
Stripe is a global payment services provider. Founded in 2010, the solution allows online merchants and vendors to accept payments for products and services offered through their own websites and mobile apps, as well as for those offered through third-party online marketplaces and platforms. Stripe works on all web-enabled devices. It has been deployed by a host of businesses globally, including online merchants, marketplaces, and platforms. The solution allows businesses to accept payments in over 135 currencies through more than...
-
Sector Analysis
NewAntibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products, Opportunities and Challenges
Antibody-Drug Conjugates Market Report Overview An Antibody-Drug Conjugates (ADC) drug consists of monoclonal antibodies conjugated to a payload via a linker, for the precise targeting of antigen-positive cancer cells. ADCs are developed to target protein receptors with high expression such as HER2, TROP-2, CD22, and others. There are two cytotoxic payload types predominantly used in ADCs including microtubule inhibitors, and the more potent DNA-damaging payloads such as topoisomerase I inhibitors. The ADC market research report will aid clients in gaining...
-
Sector Analysis
India Cold Chain Market Summary, Competitive Analysis and Forecast to 2028
Cold Chain in India industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2019-23, and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Key Highlights - Cold chain is a temperature-controlled supply chain, used to preserve and maintain the quality and integrity of perishable goods, that are sensitive to environmental conditions. Cold chains help to reduce the spoilage...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Disitamab Vedotin in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Disitamab Vedotin in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Disitamab Vedotin in Solid Tumor Drug Details: Disitamab vedotin (Aidexi)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Disitamab Vedotin in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Disitamab Vedotin in Bladder Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Disitamab Vedotin in Bladder Cancer Drug Details: Disitamab vedotin (Aidexi)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Disitamab Vedotin in Salivary Gland Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Disitamab Vedotin in Salivary Gland Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Disitamab Vedotin in Salivary Gland Cancer Drug Details: Disitamab...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Disitamab Vedotin in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Disitamab Vedotin in Esophageal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Disitamab Vedotin in Esophageal Cancer Drug Details: Disitamab vedotin (Aidexi) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Disitamab Vedotin in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Disitamab Vedotin in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Disitamab Vedotin in Metastatic Colorectal Cancer Drug Details: Disitamab vedotin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Disitamab Vedotin in Metastatic Transitional (Urothelial) Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Disitamab Vedotin in Metastatic Transitional (Urothelial) Tract Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Disitamab Vedotin in Metastatic Transitional (Urothelial) Tract...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Disitamab Vedotin in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Disitamab Vedotin in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Disitamab Vedotin in Head And Neck...